Vita 34 AG: Strong Sales Trend in the First Nine Months of 2016

Vita 34: Strong Sales Trend in the First Nine Months of 2016

- Revenues increased by 16.9 percent to EUR 12.0 million

- EBIDTA rose in annual comparison after rapid integration successes of the subsidiaries

- Internationalization moved ahead: Agreement entered into with Chinese AVIC Biology company for strategic cooperation

Leipzig, 21 November 2016 - Vita 34 AG (WKN A0BL84), the second largest stem cell bank in Europe, was able to increase revenues in the first nine months of 2016 by 16.9 percent to EUR 12.0 million (first 9 months 2015: EUR 10.3 million). Total operating revenue also increased by 16.9 percent to EUR 13.3 million (first nine months 2015: EUR 11.4 million). EBITDA totaled EUR 1.6 million and was, therefore, nearly at the prior year's level despite the integration costs for newly acquired companies (first nine months 2015: EUR 1.7 million).

Vita 34 increased the important profit figure EBITDA successively over the course of the year. As compared with the second and first quarters, EBITDA rose in third quarter, by 37% and 134% respectively. Thus, Vita 34 returned to its old profitability in Q3. EBITDA in Q3 2016 increased to EUR 0.7 million (Q3 2015: EUR 0.6 million).

Revenues increased in Q3 by some 3.6 percent to EUR 4.0 million. Total operating revenue increased by 7.6 percent to EUR 4.6 million (prior year's period: EUR 4.3 million). Apart from organic growth, the revenues from the newly acquired subsidiaries contributed to this development.

Dr. André Gerth, Chairman of the Management Board of Vita 34 AG, explains: 'We are very satisfied with the development in the current year. We have implemented the integration plan faster than planned and in addition, we have made great progress. With VitaMeins&Deins we have not only launched a new product but also have attained important milestones in the internationalization of our business model.'

Most recently, Vita 34 had entered into a cooperation agreement with the Chinese technology company AVIC Biology in the second half of the year for establishing a stem cell bank. In doing so Vita 34 is receiving milestone payments and additionally the strategic option of being further engaged in China, the largest economy in the world.

The Management Board expects an EBITDA margin towards the upper end of the forecast range of 8 -12 percent for the full year. A solid increase is also expected in revenues and total operating profit.

The complete quarterly report for the first nine months of 2016 is available immediately for download on the Internet at www.vita34group.de in the Investor Relations section.

Company Profile

Vita 34 was founded in 1997 as the first private umbilical cord blood bank in Europe and, as a complete provider, offers collection logistics, preparation and storage of umbilical cord blood. The basis for its successful work is an outstanding position in the technological segment of cryo-preservation. Here, cells and tissue are preserved alive at some -190ºC for long periods of time, and can be used if needed in the context of medical treatment. More than 150,000 families are already taking advantage of this offering and have provided for their children with a stem cell deposit at Vita 34.